Financials Island Pharmaceuticals Limited
Equities
ILA
AU0000138869
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.063 AUD | +3.28% |
|
+1.61% | -33.68% |
05-08 | Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13% | MT |
04-16 | Island Pharmaceuticals Reports Positive Data from Dose Study of Dengue Medication | MT |
Valuation
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 7.721 | 7.338 | - | - |
Enterprise Value (EV) 1 | 7.721 | 6.738 | 4.238 | 1.738 |
P/E ratio | -2.94 x | -2.1 x | -3.94 x | -4.85 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | - | -2.32 x | -1.63 x | -0.67 x |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 81,268 | 116,469 | - | - |
Reference price 2 | 0.0950 | 0.0630 | 0.0630 | 0.0630 |
Announcement Date | 8/30/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales | - | - | - | - |
EBITDA 1 | - | -2.9 | -2.6 | -2.6 |
EBIT 1 | - | -2.9 | -2.6 | -2.6 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -2.9 | -2.6 | -2.5 |
Net income 1 | -2.83 | -2.9 | -2.6 | -2.5 |
Net margin | - | - | - | - |
EPS 2 | -0.0323 | -0.0300 | -0.0160 | -0.0130 |
Free Cash Flow | - | - | - | - |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 8/30/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 0.6 | 3.1 | 5.6 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 8/30/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.68% | 4.85M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ILA Stock
- Financials Island Pharmaceuticals Limited